Head of Specialty Therapeutics

LifeStance Health•Boston, MA

9d•$252,000 - $315,000

About The Position

The Head of Specialty Therapeutics serves as a clinical authority on neuromodulation and emerging pharmacotherapies, including esketamine, ketamine, and psychedelic-assisted therapies. The role oversees safe, evidence-based specialty program development and helps position LifeStance as a national leader in interventional psychiatry. It advances specialty and interventional psychiatric therapeutics through protocols, training, quality standards, and outcome measures that support patients and align with enterprise clinical and operational priorities. The role receives strategic direction from the Senior Leader, Psychiatric Excellence & Emerging Therapeutics and independently leads specialty therapeutic strategy, clinical standards, program design, and outcome measurement recommendations. It makes day-to-day decisions on protocol development, provider education, quality monitoring, evidence review, and program improvement, escalating matters involving higher-risk interventions, regulatory requirements, patient safety, significant investment, expansion, vendor selection, or enterprise policy. The position may supervise direct reports or contractors as programs scale and provides functional leadership to clinical workgroups and cross-functional partners. The ideal candidate is collaborative, mission-driven, emotionally intelligent, judicious, and effective in a high-accountability environment. They communicate thoughtfully, remain solutions-oriented under pressure, and prioritize shared goals. All LifeStance team members are expected to support colleagues and the mission, including by participating in projects and performing responsibilities beyond those specifically listed.

Requirements

MD or DO with board certification in Psychiatry.
Active, unrestricted medical license and ability to maintain appropriate licensure requirements.
At least 10 years of psychiatric clinical experience, including experience with specialty, interventional, or advanced psychiatric treatment modalities.
Demonstrated ability to develop clinical protocols, care pathways, safety standards, training models, or program governance structures.
Strong understanding of clinical evidence review, patient safety, risk management, regulatory considerations, and standards of care for specialty therapeutics.
Ability to influence clinical and operational leaders across a complex, matrixed organization.
Excellent written, verbal, facilitation, and executive communication skills.
Legally authorized to be employed in the United States.
Demonstrates awareness, inclusivity, sensitivity, humility, and experience working with individuals from diverse ethnic backgrounds, socioeconomic statuses, sexual orientations, gender identities, and other aspects of culture.

Nice To Haves

Experience developing, leading, or scaling specialty psychiatric treatment programs such as TMS, ketamine/esketamine, or other advanced therapeutic modalities.
Clinical research, evidence-generation, or outcomes evaluation experience.
Experience in large multi-site, multi-state, or enterprise healthcare organizations.
Experience partnering with academic, research, vendor, or specialty treatment organizations.

Responsibilities

Design and implement an enterprise interventional psychiatry strategy encompassing TMS, including rapid protocols, emerging pharmacotherapies, and neuromodulation modalities.
Lead clinical program development for psychedelic-assisted therapies, including psilocybin, MDMA, and other emerging agents, in alignment with current and future FDA guidance and DEA requirements.
Evaluate emerging specialty treatments based on evidence, regulatory requirements, safety, operational feasibility, and patient need.
Monitor and synthesize emerging interventional psychiatry literature to inform strategy and competitive positioning.
Develop clinical protocols, eligibility criteria, care pathways, quality standards, and safety-monitoring expectations for specialty therapeutic programs.
Oversee implementation, performance monitoring, and continuous improvement of specialty therapeutic services across applicable markets and care settings.
Oversee training and credentialing standards for clinicians delivering interventional therapies, including structured psychotherapy integration where required by emerging FDA guidance.
Partner with Medical Leadership, Clinical Operations, Quality, Research, and Finance to ensure programs are clinically sound, operationally feasible, and responsibly governed.
Partner with legal, compliance, and operations teams to navigate DEA Schedule I licensing if necessary, REMS requirements, and state-level regulatory variation.
Collaborate with the Director of Emerging and Digital Therapeutics on data collection and outcome-measurement frameworks.
Monitor outcomes, adverse events, utilization trends, patient experience, and effectiveness measures to guide program improvement and scale decisions.
Build relationships with academic institutions, research organizations, specialty therapy centers, and external experts to inform clinical strategy and evidence generation.
Provide functional leadership to clinical workgroups, specialty program teams, and cross-functional implementation partners; may supervise direct reports or contractors as programs scale.
Support provider education, expert consultation, program governance, and accountability for safe, evidence-based program execution.